Ketamine Therapy

Cost:

$249 1 hour infusion
$449 2 hour infusion
$236.75/infusion bundle package

Ketamine is considered off label by the FDA for pain infusion and mood disorder. This does not mean it is unsafe. But most insurance will not cover these treatments as they consider them “experimental.” However, there are over 20 years of history behind these treatments.

Ketamine is getting attention for both pain relief and mood stabilization. We can safely give you the same treatment as our neighbors in Chattanooga with the ease of being right here in Cleveland.

We at Cleveland Pain Medicine have worked hard to give you the best possible experience.

History

Ketamine was introduced into clinical practice in the 1960’s and continues to be both clinically useful for anesthetic, pain and psychiatric medicine. Ketamine remains invaluable to the fields of anesthesiology and critical care medicine, in large part due to its ability to maintain cardiac and respiratory function while providing an effective dissociative anesthetic. Furthermore, there may be an emerging role in the treatment of refractory depression and Post-Traumatic Stress Disorder, Alzheimer’s, Parkinson’s, and autism.

Time Tested

Anesthesiologists agree ketamine appears to have a significant effect on chronic pain, CRPS, depression, PTSD and anxiety.

Ketamine is safe and effective when used in low doses and administered by knowledgeable registered nurses working under an ABMS board certified anesthesiologist.

Multiple Beneficial Effects

Before we start any treatment for a mental health condition, you must first talk to your mental health provider and get mental health clearance.

If you require Ketamine infusion for a pain related condition, we can provide a pain consultation here at Cleveland Pain Medicine. We will investigate the source of your pain, review your previous therapies and then offer you a variety of treatment options including Ketamine Infusion if that is the right treatment for you.

Studies:

Here are some studies showing the benefits of ketamine infusions:

https://pubmed.ncbi.nlm.nih.gov/29727073/

This study, the first open-label study of repeated ketamine infusions in a comorbid population, found rapid and sustained improvement in PTSD and depression symptoms. This report suggests that repeated ketamine treatments are safe and may represent an efficacious treatment for individuals with comorbid PTSD and TRD.

https://pubmed.ncbi.nlm.nih.gov/28670718/

Chronic cluster headache (CH) is a rare, highly disabling primary headache condition. As NMDA receptors are possibly overactive in CH, NMDA receptor antagonists, such as ketamine, could be of interest in patients with intractable CH.

Case reports: Two Caucasian males, 28 and 45 years-old, with chronic intractable CH, received a single ketamine infusion (0.5 mg/kg over 2 h) combined with magnesium sulfate (3000 mg over 30 min) in an outpatient setting. This treatment led to a complete relief from symptoms (attack frequency and pain intensity) for one patient and partial relief (50%) for the other patient, for 6 weeks in both cases.

https://rsds.org/wp-content/uploads/2017/04/intravenous-ketamine-infusions-neuropathic-pain-mgt.pdf

On the basis of the available evidence, a successful ket- amine infusion protocol for the treatment of chronic neu- ropathic pain would include several components: (1) applying the longest possible infusion duration that is logistically feasible using multiple outpatient clinic vis- its if necessary; (2) using a dose of ketamine between 0.1 and 0.5 mg/kg/h to avoid excessive sedation in the major- ity of patients; and (3) utilizing adjunct medications such as midazolam to decrease the incidence of psychomimetic side effects and possibly improve the degree of pain relief. All infusions should be done in a monitored setting with standard American Society of Anesthesiology monitors under physician supervision. Although a dose of ketamine between 0.1 and 0.5 mg/kg/h does not eliminate the need for monitoring of the risk of sedation, safe and effective use of this range has been reported in the monitored outpatient, non-ICU setting